Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study
Source
PLoS ONE - ISSN 1932-6203-19:7 (2024) p. 1-15
Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma : protocol of a monocentric phase I/II clinical trial in Belgium
Source
BMJ open - ISSN 2044-6055-14:3 (2024) p. 1-10
Analysis of Wilms’ tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed
Source
- () p.
Combined results of two cross-sectional surveys on the participation in clinical trials and the e-consent procedure in the landscape of haematology
Source
Clinics and practice - ISSN 2039-7275-13:6 (2023) p. 1520-1531
Decentralised, point-of-care CAR-T for multiple myeloma
Source
The lancet oncology - ISSN 1470-2045-24:8 (2023) p. 828-830